Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

16.47 -0.08 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,231,020
Open 16.39
Bid (Size) 15.50 (1)
Ask (Size) 16.60 (1)
Prev. Close 16.55
Today's Range 16.25 - 16.59
52wk Range 7.931 - 25.29
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-13.2%
-13.2%
1 Month
+13.4%
+13.4%
3 Month
+13.6%
+13.6%
6 Month
-9.0%
-9.0%
1 Year
+68.2%
+68.2%

More News

Read More
Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
7 Analysts Assess Travere Therapeutics: What You Need To Know
Via Benzinga
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
From Travere Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
From Travere Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
From Pomerantz LLP
Via GlobeNewswire
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
From Travere Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why
Via Investor's Business Daily
Topics Government

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?
Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
What is the current price of Travere Therapeutics, Inc. - Common Stock?
The current price of Travere Therapeutics, Inc. - Common Stock is 16.47
When was Travere Therapeutics, Inc. - Common Stock last traded?
The last trade of Travere Therapeutics, Inc. - Common Stock was at 07/11/25 04:00 PM ET
What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
The market capitalization of Travere Therapeutics, Inc. - Common Stock is 1.00B
How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
Travere Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.